(NASDAQ: ABEO) Abeona Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.31%.
Abeona Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ABEO's revenue for 2024 to be $476,458,367, with the lowest ABEO revenue forecast at $476,458,367, and the highest ABEO revenue forecast at $476,458,367. On average, 4 Wall Street analysts forecast ABEO's revenue for 2025 to be $685,450,333, with the lowest ABEO revenue forecast at $433,143,970, and the highest ABEO revenue forecast at $1,065,534,166.
In 2026, ABEO is forecast to generate $2,442,931,991 in revenue, with the lowest revenue forecast at $1,645,947,086 and the highest revenue forecast at $3,131,630,903.